BlossomHill Therapeutics (NASDAQ:BLSM) Raised to "Hold" at Zacks Research

Key Points

• Zacks Research upgraded BlossomHill Therapeutics to “Hold,” while five other analysts maintain Buy ratings. The stock has a “Moderate Buy” consensus rating and an average price target of $32.20, versus a $20.02 opening price.
• Several firms recently initiated bullish coverage, including HC Wainwright with a $35 target, Lifesci Capital at $32, Leerink Partners at $36, Guggenheim at $30, and JPMorgan at $28.
• Insider buying has been substantial: insiders purchased 1.57 million shares worth approximately $25.2 million over the past three months, including a $10 million purchase by Director Carl Gordon.

BlossomHill Therapeutics (NASDAQ:BLSM - Get Free Report) was upgraded by equities research analysts at Zacks Research to a "hold" rating in a research note issued on Wednesday, Zacks reports.

Other research analysts also recently issued research reports about the company. HC Wainwright assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They set a "buy" rating and a $35.00 price target on the stock. Lifesci Capital initiated coverage on BlossomHill Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $32.00 price objective for the company. Leerink Partners assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $36.00 price objective for the company. Guggenheim initiated coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set a "buy" rating and a $30.00 target price on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They issued an "overweight" rating and a $28.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $32.20.

BlossomHill Therapeutics Stock Performance

Shares of NASDAQ:BLSM opened at $20.02 on Wednesday. BlossomHill Therapeutics has a 12 month low of $15.25 and a 12 month high of $20.61.

Insider Buying and Selling

In related news, Director John P. Schmid acquired 6,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $96,000.00. Following the transaction, the director directly owned 6,000 shares in the company, valued at approximately $96,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Carl Gordon acquired 625,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the purchase, the director directly owned 2,714,279 shares of the company's stock, valued at $43,428,464. The trade was a 29.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 1,573,900 shares of company stock worth $25,181,900 over the last three months.

Key Headlines Impacting BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners initiated coverage with an Outperform rating and a $36 price target, while HC Wainwright began coverage with a Buy rating and a $35 target. These targets imply substantial potential appreciation if the company executes successfully. BlossomHill Therapeutics Research Coverage Started at Leerink Partners BlossomHill Therapeutics Research Coverage Started at HC Wainwright
• Positive Sentiment: Guggenheim also initiated coverage with a Buy rating and a $30 price target. The cluster of bullish initiations provides broader sell-side validation for BLSM. BlossomHill Therapeutics Research Coverage Started at Guggenheim
• Positive Sentiment: Additional coverage was initiated by JPMorgan Chase and Lifesci Capital, increasing institutional visibility for the clinical-stage cancer drug developer.
• Positive Sentiment: BlossomHill announced upcoming presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events could give investors more information about its small-molecule oncology pipeline and development progress. BlossomHill Therapeutics Conference Presentations
• Neutral Sentiment: HC Wainwright continues to forecast losses, including fiscal 2026 EPS of approximately ($3.71) and fiscal 2027 EPS of ($2.99). However, its estimates improve through 2027, supporting the firm’s Buy rating and $35 price objective.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source